Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 4/20 | 0.53 |
| ▸ | ADA | P00813 | 1/20 | 0.53 |
| ▸ | PI4KA | P42356 | 3/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14064196 | 1.00 | AHCY (0.53) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL887899 | 0.89 | ADA (0.61) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL20059210 | 0.89 | ADA (0.61) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL13790712 | 0.89 | ADA (0.61) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL25496381 | 0.88 | AHCY (0.53) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL18519971 | 0.87 | POLB (0.52) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL26189592 | 0.87 | POLB (0.62) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL14639883 | 0.87 | POLB (0.62) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL12837026 | 0.87 | POLB (0.62) | AHCYADAPI4KAPI4K2BPI4K2A | |
| SCHEMBL12352424 | 0.87 | POLB (0.62) | AHCYADAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-8008007-B2 | S-adenosyl-L-methionine analogs with extended activated groups for transfer by methyltransferases | RWTH AACHEN (DE) | 2011-08-30 | — | — | US | disclosed |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | RWTH AACHEN (DE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | AHCY 3405/4885ADA 1726/4885PI4KA 829/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | AHCY 3405/4885ADA 1726/4885PI4KA 829/4885 |
| US-20090018101-A1 | S-ADENOSYL-L-METHIONINE ANALOGS WITH EXTENDED ACTIVATED GROUPS FOR TRANSFER BY METHYLTRANSFERASES | BHMT2, MSRB3, PRMT3 | AHCY 29/4885ADA 277/4885PI4KA 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.